| Primary information |
|---|
| sequence ID | Seq_9311 |
| Peptide sequence | VSEDPINDGEWHRVTA |
| CancerPDF_ID | CancerPDF_ID10332, CancerPDF_ID11079, |
| PMID | 21805675,26482227 |
| Protein Name | Basement membrane-specific heparan sulfate proteoglycan core protein,PGBM_HUMAN |
| UniprotKB Entry Name | PGBM_HUMAN,PGBM_HUMAN |
| Fluid | Urine,Urine |
| M/Z | 1824.8244,1825.638 |
| Charge | NA,NA |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | MALDI-TOF-MS,LC-ESI-MS/MS |
| Quantification Technique | NA,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | 1,FDR less than 5 % |
| CancerPDF_ID | CancerPDF_ID10332, CancerPDF_ID11079, |
| p-Value | NA,NA |
| Software | NA,MASCOT |
| Length | 16,NA |
| Cancer Type | Muscle-invasive bladder cancer,Clear cell renal carcinoma |
| Database | SwissProt Database,SwissProt Database |
| Modification | NA,NA |
| Number of Patients | 751 bladder cancer and 127 control,"117 clear cell RCC patients (ccRCC) (72 men, 45 women)" |
| Regulation | Differentially expressed between cancer vs normal samples,"Differentially expression in control vs ccRCC cancer, Primary Tumor or grade" |
| Validation | Mann-Whitney tests and areas under receiver-operator characteristic,external cross validation not done |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | |